MIRD pamphlet No. 22 (Abridged): Radiobiology and dosimetry of α-particle emitters for targeted radionuclide therapy

Journal of Nuclear Medicine

Volumn 51, Issue 2, 2010, Pages 311-328

  Sgouros, George ^a   Roeske, John C ^b   McDevitt, Michael R ^c   Palm, Stig ^d   Allen, Barry J ^e   Fisher, Darrell R ^f   Brill, A Bertrand ^g   Song, Hong ^a   Howell, Roger W ^h   Akabani, Gamal ⁱ   Bolch, Wesley E ^j   Meredith, Ruby F ^j   Wessels, Barry W ^j   Zanzonico, Pat B ^j  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d INTERNATIONAL ATOMIC ENERGY AGENCY   (Austria)

^e St George Cancer Care Center   (Australia)

^f PACIFIC NORTHWEST NATIONAL LABORATORY   (United States)

^g VANDERBILT UNIVERSITY   (United States)

^h RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

ⁱ Texas AandM University   (United States)

^j NONE

more..

Author keywords

particle emitters; Human particle emitter dosimetry; Targeted particle emitter therapy

Indexed keywords

ACTINIUM 225; ASTATINE 211; BISMUTH 213; IODINE 131; OXYGEN; PLACEBO; POLONIUM; RADIOISOTOPE; RADIUM 223; RITUXIMAB; UNCLASSIFIED DRUG; YTTRIUM 90;

ACUTE GRANULOCYTIC LEUKEMIA; ALPHA RADIATION; BONE MARROW; BONE METASTASIS; BREAST CANCER; CARCINOGENESIS; CELL SURVIVAL; CLINICAL TRIAL; DOSIMETRY; GLIOBLASTOMA; HUMAN; MEDICAL RESEARCH; MELANOMA; MICRODOSIMETRY; MYELOID LEUKEMIA; NONHODGKIN LYMPHOMA; NONHUMAN; OVARY CARCINOMA; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION DOSE; RADIATION DOSE FRACTIONATION; RADIOBIOLOGY; RADIOIMMUNOTHERAPY; RELATIVE BIOLOGIC EFFECTIVENESS; REVIEW;

ALPHA PARTICLES; CELL DEATH; CELL SURVIVAL; CLINICAL TRIALS AS TOPIC; DOSE-RESPONSE RELATIONSHIP, RADIATION; FEMALE; HUMANS; MALE; NEOPLASMS; NEOPLASMS, RADIATION-INDUCED; PAMPHLETS; RADIATION-PROTECTIVE AGENTS; RADIOBIOLOGY; RADIOISOTOPES; RADIOTHERAPY DOSAGE; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; RELATIVE BIOLOGICAL EFFECTIVENESS; SOCIETIES, MEDICAL;

EID: 75749110617     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.108.058651     Document Type: Review

References (155)

1. 90Y. Int J Radiat Oncol Biol Phys. 1984;10:341-348.
2. Macklis RM, Kinsey BM, Kassis AI, et al. Radioimmunotherapy with alpha-particle emitting immunoconjugates. Science. 1988;240:1024-1026.
3. Zalutsky MR, Vaidyanathan G. Astatine-211-labeled radiotherapeutics: an emerging approach to targeted alpha-particle radiotherapy. Curr Pharm Des. 2000;6:1433-1455.
4. McDevitt MR, Ma D, Lai LT, et al. Tumor therapy with targeted atomic nanogenerators. Science. 2001;294:1537-1540.
5. McDevitt MR, Sgouros G, Finn RD, et al. Radioimmunotherapy with alpha-emitting nuclides. Eur J Nucl Med. 1998;25:1341-1351.
6. Mulford DA, Scheinberg DA, Jurcic JG. The promise of targeted α-particle therapy. J Nucl Med. 2005;46(suppl 1):199S-204S.
7. Jurcic JG. Antibody therapy for residual disease in acute myelogenous leukemia. Crit Rev Oncol Hematol. 2001;38:37-45.
8. Wilbur DS. Potential use of alpha-emitting radionuclides in the treatment of cancer. Antibody Immunoconjugates Radiopharm. 1990;4:85-97.
9. Wicha MS. Cancer stem cells and metastasis: lethal seeds [commentary]. Clin Cancer Res. 2006;12:5606-5607.
10. 213Bi: mathematical modeling and feasibility analysis. Cancer Biother Radiopharm. 2008;23:74-81.
11. Jurcic JG, Larson SM, Sgouros G, et al. Targeted alpha particle immunotherapy for myeloid leukemia. Blood. 2002;100:1233-1239.
12. Jurcic JG, McDevitt MR, Sgouros G, et al. Targeted alpha-particle therapy for myeloid leukemias: a phase I trial of bismuth-213-HuM195 (anti-CD33) [abstract]. Blood. 1997;90:2245.
13. 225Ac as a source of alpha-particles in radioimmunotherapy. Nucl Med Commun. 1993;14:121-125.
14. 211Atlabeled chimeric antitenascin monoclonal antibody 81C6. J Nucl Med. 2008;49:30-38.
15. Nilsson S, Larsen RH, Fossa SD, et al. First clinical experience with alpha-emitting radium-223 in the treatment of skeletal metastases. Clin Cancer Res. 2005;11:4451-4459.
16. 211At-MX35 F(AB')(2) in therapy of ovarian cancer: preliminary results from an ongoing phase I study [abstract]. Cancer Biother Radiopharm. 2006;21:395.
17. 211At. Radiat Res. 2002;157:633-641.
18. 213Bi: an alpha-particle emitter. Nucl Med Biol. 1998;25:241-246.
19. Akabani G, McLendon RE, Bigner DD, Zalutsky MR. Vascular targeted endoradiotherapy of tumors using alpha-particle-emitting compounds: theoretical analysis. Int J Radiat Oncol Biol Phys. 2002;54:1259-1275.
20. 225Ac radioimmunopharmaceuticals. Appl Radiat Isot. 2002;57:841-847.
21. Jurcic JG, McDevitt MR, Pandit-Taskar N, et al. Alpha-particle immunotherapy for acute myeloid leukemia (AML) with bismuth-213 and actinium-225 [abstract]. Cancer Biother Radiopharm. 2006;21:396.
22. Zirkle RE. Some effects of alpha radiation upon plant cells. J Cell Comp Physiol. 1932;2:251-274.
23. Brown A, Suit H. The centenary of the discovery of the Bragg peak. Radiother Oncol. 2004;73:265-268.
24. Barendsen GW, Koot CJ, van Kerson GR, Bewley DK, Field SB, Parnell CJ. The effect of oxygen on the impairment of the proliferative capacity of human cells in culture by ionizing radiations of different LET. Int J Radiat Biol. 1966;10:317-327.
25. Barendsen GW, Walter HMD. Effects of different ionizing radiations on human cells in tissue culture. IV. Modification of radiation damage. Radiat Res. 1964;21:314-329.
26. Barendsen GW. Modification of radiation damage by fractionation of dose anoxia + chemical protectors in relation to LET. Ann N Y Acad Sci. 1964;114(A1):96-114.
27. Barendsen GW. Impairment of the proliferative capacity of human cells in culture by alpha-particles with differing linear-energy transfer. Int J Radiat Biol Relat Stud Phys Chem Med. 1964;8:453-466.
28. Barendsen GW, Walter HMD, Bewley DK, Fowler JF. Effects of different ionizing radiations on human cells in tissue culture. III. Experiments with cyclotron-accelerated alpha-particles and deuterons. Radiat Res. 1963;18:106.
29. Barendsen GW. Dose-survival curves of human cells in tissue culture irradiated with alpha-, beta-, 20-kv x- and 200-kv x-radiation. Nature. 1962;193:1153.
30. Barendsen GW, Beusker TLJ. Effects of different ionizing radiations on human cells in tissue culture. I. Irradiation techniques and dosimetry. Radiat Res. 1960;13:832-840.
31. Barendsen GW, Beusker TLJ, Vergroesen AJ, Budke L. Effect of different ionizing radiations on human cells in tissue culture. II. Biological experiments. Radiat Res. 1960;13:841-849.
32. Barendsen GW, Vergroesen AJ. Irradiation of human cells in tissue culture with alpha-rays, beta-rays and x-rays [abstract]. Int J Radiat Biol Relat Stud Phys Chem Med. 1960;2:441.
33. Goodhead DT, Munson RJ, Thacker J, Cox R. Mutation and inactivation of cultured mammalian cells exposed to beams of accelerated heavy ions. IV. Biophysical interpretation. Int J Radiat Biol Relat Stud Phys Chem Med. 1980;37:135-167.
34. Munson RJ, Bance DA, Stretch A, Goodhead DT. Mutation and inactivation of cultured mammalian cells exposed to beams of accelerated heavy ions. I. Irradiation facilities and methods. Int J Radiat Biol Relat Stud Phys Chem Med. 1979;36:127-136.
35. Thacker J, Stretch A, Stephens MA. Mutation and inactivation of cultured mammalian cells exposed to beams of accelerated heavy ions. II. Chinese hamster V79 cells. Int J Radiat Biol Relat Stud Phys Chem Med. 1979;36:137-148.
36. Cox R, Masson WK. Mutation and inactivation of cultured mammalian cells exposed to beams of accelerated heavy ions. III. Human diploid fibroblasts. Int J Radiat Biol Relat Stud Phys Chem Med. 1979;36:149-160.
37. Fisher DR, Frazier ME, Andrews TK Jr. Energy distribution and the relative biological effects of internal alpha emitters. Radiat Prot Dosimetry. 1985;13:223-227.
38. Humm JL, Chin LM. A model of cell inactivation by alpha-particle internal emitters. Radiat Res. 1993;134:143-150.
39. Kvinnsland Y, Stokke T, Aurlien E. Radioimmunotherapy with alpha-particle emitters: microdosimetry of cells with a heterogeneous antigen expression and with various diameters of cells and nuclei. Radiat Res. 2001;155:288-296.
40. Neti PVSV, Howell RW. Log normal distribution of cellular uptake of radioactivity: implications for biologic responses to radiopharmaceuticals. J Nucl Med. 2006;47:1049-1058.
41. Munro TR. Relative radiosensitivity of nucleus and cytoplasm of Chinese hamster fibroblasts. Radiat Res. 1970;42:451-470.
42. Lloyd EL, Gemmell MA, Henning CB, Gemmell DS, Zabransky BJ. Cell survival following multiple-track alpha particle irradiation. Int J Radiat Biol Relat Stud Phys Chem Med. 1979;35:23-31.
43. Raju MR, Eisen Y, Carpenter S, Inkret WC. Radiobiology of alpha particles. III. Cell inactivation by alpha particle traversals of the cell nucleus. Radiat Res. 1991;128:204-209.
44. Bird RP, Rohrig N, Colvett RD, Geard CR, Marino SA. Inactivation of synchronized Chinese hamster V79 cells with charged-particle track segments. Radiat Res. 1980;82:277-289.
45. Todd P, Wood JCS, Walker JT, Weiss SJ. Lethal, potentially lethal, and nonlethal damage induction by heavy-ions in cultured human-cells. Radiat Res. 1985;104(suppl):S5-S12.
46. 238Pu alpha-particles on the mouse fibroblast cell line C3H 10T1/2: characterization of source and RBE for cell survival. Int J Radiat Biol Relat Stud Phys Chem Med. 1987;52:871-882.
47. Barendsen GW. LET dependence of linear and quadratic terms in dose-response relationships for cellular-damage: correlations with the dimensions and structures of biological targets. Radiat Prot Dosimetry. 1990;31:235-239.
48. Howell RW, Rao DV, Hou DY, Narra VR, Sastry KSR. The question of relative biological effectiveness and quality factor for auger emitters incorporated into proliferating mammalian cells. Radiat Res. 1991;128:282-292.
49. Macklis RM, Lin JY, Beresford B, Atcher RW, Hines JJ, Humm JL. Cellular kinetics, dosimetry, and radiobiology of alpha-particle radioimmunotherapy: induction of apoptosis. Radiat Res. 1992;130:220-226.
50. Charlton DE, Nikjoo H, Humm JL. Calculation of initial yields of single-strand and double-strand breaks in cell-nuclei from electrons, protons and alpha-particles. Int J Radiat Biol. 1989;56:1-19.
51. Charlton DE, Turner MS. Use of chord lengths through the nucleus to simulate the survival of mammalian cells exposed to high LET alpha-radiation. Int J Radiat Biol. 1996;69:213-217.
52. Crawford-Brown DJ, Hofmann W. A generalized state-vector model for radiation-induced cellular transformation. Int J Radiat Biol. 1990;57:407-423.
53. Crawford-Brown DJ, Hofmann W. Correlated hit probability and cell transformation in an effect-specific track length model applied to in vitro alpha irradiation. Radiat Environ Biophys. 2001;40:317-323.
54. Holthusen H. Articles on the biology of radiation effects: analysis on nematode eggs. Pflugers Arch Gesamte Physiol Menschen Tiere. 1921;187:1-24.
55. Thomlinson RH, Gray LH. The histological structure of some human lung cancers and the possible implications for radiotherapy. Br J Cancer. 1955;9:539-549.
56. Unruh A, Ressel A, Mohamed HG, et al. The hypoxia-inducible factor-1 alpha is a negative factor for tumor therapy. Oncogene. 2003;22:3213-3220.
57. Ewing D, Powers EL. Oxygen-dependent sensitization of irradiated cells. In: Meyn RE, Withers HR, eds. Radiation Biology in Cancer Research. New York, NY: Raven Press; 1979:143-168.
58. Hall EJ. Radiobiology for the Radiologist. Philadelphia, PA: JB Lippincott Co.; 1994:118.
59. Machinami R, Ishikawa Y, Boecker BB. The international workshop on health effects of Thorotrast, radium, radon and other alpha-emitters, 1999 [preface]. Radiat Res. 1999;152(suppl):S1-S2.
60. R). Philadelphia, PA: Elsevier; 2004. ICRP publication 92.
61. Harrison JD, Muirhead CR. Quantitative comparisons of cancer induction in humans by internally deposited radionuclides and external radiation. Int J Radiat Biol. 2003;79:1-13.
62. Brown I, Mitchell JS. The development of a [At-211]-astatinated endoradio-therapeutic drug: Part IV - late radiation effects. Int J Radiat Oncol Biol Phys. 1998;40:1177-1183.
63. Durbin PW, Asling CW, Johnston ME, et al. The induction of tumors in the rat by astatine-211. Radiat Res. 1958;9:378-397.
64. Yokoro K, Kunii A, Furth J, Durbin PW. Tumor induction with astatine-211 in rats: characterization of pituitary tumors. Cancer Res. 1964;24:683-688.
65. Hall EJ, Brenner DJ. The radiobiology of radiosurgery: rationale for different treatment regimes for AVMs and malignancies. Int J Radiat Oncol Biol Phys. 1993;25:381-385.
66. Dale RG, Jones B. The assessment of RBE effects using the concept of biologically effective dose. Int J Radiat Oncol Biol Phys. 1999;43:639-645.
67. Takata M, Sasaki MS, Sonoda E, et al. Homologous recombination and non-homologous end-joining pathways of DNA double-strand break repair have overlapping roles in the maintenance of chromosomal integrity in vertebrate cells. EMBO J. 1998;17:5497-5508.
68. Oliveira NG, CastroM, Rodrigues AS, et al.Wortmannin enhances the induction of micronuclei by low and high LET radiation [erratum]. Mutagenesis. 2003;18:217.
69. Oliveira NG, Castro M, Rodrigues AS, et al. Wortmannin enhances the induction of micronuclei by low and high LET radiation. Mutagenesis. 2003;18:37-44.
70. Harapanhalli RS, Narra VR, Yaghmai V, et al. Vitamins as radioprotectors in vivo. II. Protection by vitamin A and soybean oil against radiation-damage caused by internal radionuclides. Radiat Res. 1994;139:115-122.
71. Narra VR, Harapanhalli RS, Goddu SM, Howell RW, Rao DV. Radioprotection against biological effects of internal radionuclides in vivo by S-(2-aminoethyl)isothiouronium bromide hydrobromide (AET). J Nucl Med. 1995;36:259-266.
72. 125I compared with that of densely ionizing alpha-particles. Lancet. 1989;2:650-653.
73. Rao DV, Narra VR, Howell RW, Lanka VK, Sastry KSR. Induction of sperm head abnormalities by incorporated radionuclides: dependence on subcellular distribution, type of radiation, dose rate, and presence of radioprotectors. Radiat Res. 1991;125:89-97.
74. Goddu SM, Narra VR, Harapanhalli RS, Howell RW, Rao DV. Radioprotection by DMSO against the biological effects of incorporated radionuclides in vivo: comparison with other radioprotectors and evidence for indirect action of Auger electrons. Acta Oncol. 1996;35:901-907.
75. Narra VR, Harapanhalli R, Howell RW, Sastry KSR, Rao DV. Vitamins as radioprotectors in vivo. I. Protection by vitamin C against internal radionuclides in mouse testes: implications to the mechanism of damage caused by the Auger effect. Radiat Res. 1994;137:394-399.
76. Wright HA, Magee JL, Hamm RN, Chatterjee A, Turner JE, Klots CE. Calculations of physical and chemical-reactions produced in irradiated water containing DNA. Radiat Prot Dosimetry. 1985;13:133-136.
77. International Commission on Radiological Protection. RBE for Deterministic Effects. Philadelphia, PA: Elsevier; 1990. ICRP publication 58.
78. Schwartz JL, Rotmensch J, Atcher RW, et al. Interlaboratory comparison of different alpha-particle and radon sources: cell survival and relative biological effectiveness. Health Phys. 1992;62:458-461.
79. Jostes RF, Hui TE, James AC, et al. In vitro exposure of mammalian cells to radon: dosimetric considerations. Radiat Res. 1991;127:211-219.
80. Charlton DE, Utteridge TD, Allen BJ. Theoretical treatment of human haemopoietic stem cell survival following irradiation by alpha particles. Int J Radiat Biol. 1998;74:111-118.
81. Howell RW, Goddu SM, Narra VR, Fisher DR, Schenter RE, Rao DV. Radiotoxicity of gadolinium-148 and radium-223 in mouse testes: relative biological effectiveness of alpha-particle emitters in vivo. Radiat Res. 1997;147:342-348.
82. Howell RW, Goddu SM, Rao DV. Design and performance characteristics of an experimental cesium-137 irradiator to simulate internal radionuclide dose rate patterns. J Nucl Med. 1997;38:727-731.
83. 32P-orthophosphate: implications for therapy of bone pain and bone metastases. J Nucl Med. 2000;41:941-951.
84. Feinendegen LE, McClure JJ. Meeting report: Alpha-emitters for medical therapy - Workshop of the United States Department of Energy, Denver, Colorado, May 30-31, 1996. Radiat Res. 1997;148:195-201.
85. 1990 recommendations of the International Commission on Radiological Protection. Ann ICRP. 1991;21:1-201.
86. Radiation protection in medicine: ICRP publication 105. Ann ICRP. 2007;37: 1-63.
87. 210Po in multicellular clusters. Radiat Res. 2007;168:332-340.
88. Goddu SM, Rao DV, Howell RW. Multicellular dosimetry for micrometastases: dependence of self-dose versus cross-dose to cell nuclei on type and energy of radiation and subcellular distribution of radionuclides. J Nucl Med. 1994;35:521-530.
89. Charlton DE. Radiation effects in spheroids of cells exposed to alpha emitters. Int J Radiat Biol. 2000;76:1555-1564.
90. Akabani G, Zalutsky MR. Microdosimetry of astatine-211 using histological images: application to bone marrow. Radiat Res. 1997;148:599-607.
91. Humm JL, Macklis RM, Bump K, Cobb LM, Chin LM. Internal dosimetry using data derived from autoradiographs. J Nucl Med. 1993;34:1811-1817.
92. Baxter LT, Jain RK. Transport of fluid and macromolecules in tumors. IV. A microscopic model of the perivascular distribution. Microvasc Res. 1991;41:252-272.
93. Jain RK, Baxter LT. Mechanisms of heterogeneous distribution of monoclonal antibodies and other macromolecules in tumors: significance of elevated interstitial pressure. Cancer Res. 1988;48:7022-7032.
94. Sgouros G. Plasmapheresis in radioimmunotherapy of micrometastases: a mathematical modeling and dosimetrical analysis. J Nucl Med. 1992;33: 2167-2179.
95. Goddu SM, Howell RL, Bouchet LG, Bolch WE, Rao DV. MIRD Cellular S Values. Reston VA: Society of Nuclear Medicine; 1997.
96. Goddu SM, Howell RW, Rao DV. Cellular dosimetry: absorbed fractions for monoenergetic electron and alpha particle sources and S-values for radionuclides uniformly distributed in different cell compartments. J Nucl Med. 1994;35:303-316.
97. Polig E. Localized alpha-dosimetry. In: Eberg M, Howard A, eds. Current Topics in Radiation Research. Vol 13. Amsterdam, The Netherlands: Elsevier; 1978:189-327.
98. Rossi HH. Microdosimetric energy distribution in irradiated matter. In: Attx FH, Roesch WC, eds. Radiation Dosimetry. Vol 1. New York, NY: Academic Press; 1968.
99. Roesch WC. Microdosimetry of internal sources. Radiat Res. 1977;70:494-510.
100. Fisher DR. The microdosimetry of monoclonal antibodies labeled with alpha emitters. In: Schlafke-Stelson AT, Watson EE, eds. Fourth International Radiopharmaceutical Dosimetry Symposium. Oak Ridge, TN: Oak Ridge Associated Universities; 1986:26-36.
101. Stinchcomb TG, Roeske JC. Analysis of survival of C-18 cells after irradiation in suspension with chelated and ionic bismuth-212 using microdosimetry. Radiat Res. 1994;140:48-54.
102. Stinchcomb TG, Roeske JC. Analytic microdosimetry for radioimmunotherapeutic alpha emitters. Med Phys. 1992;19:1385-1393.]
103. Kellerer AM. Analysis of patterns of energy deposition: a survey of theoretical relations in microdosimetry. In: Ebert HG, ed. Proceedings of the Second Symposium on Microdosimetry. Brussels, Belgium: Commission of European Communities; 1970:107-134.
104. Olko P, Booz J. Energy deposition by protons and alpha-particles in spherical sites of nanometer to micrometer diameter. Radiat Environ Biophys. 1990;29:1-17.
105. Ziegler JF, Biersack JP, Littmark U. The Stopping and Range of Ions in Matter. New York, NY, Pergamon Press; 1985.
106. Ziegler JF. The stopping and range of ions in solids (Stopping and Range of Ions in Matter, Vol. 1). New York, NY: Pergamon; 1985.
107. Bichsel H. Stopping Powers of Fast Charged Particles in Heavy Elements. Springfield, VA: U.S. National Technical Information Service; 1992. NIST report IR-4550.
108. International Commission on Radiation Units and Measurements. Stopping Powers and Ranges for Protons and Alpha Particles. Bethesda, MD: ICRU; 1993. ICRU publication 49.
109. Kellerer AM, Chmelevsky D. Criteria for applicability of LET. Radiat Res. 1975;63:226-234.
110. Roeske JC, Stinchcomb TG. Dosimetric framework for therapeutic alpha-particle emitters. J Nucl Med. 1997;38:1923-1929.
111. Loevinger R, Budinger TF, Watson EE. MIRD Primer for Absorbed Dose Calculations. Revised ed. New York, NY: Society of Nuclear Medicine; 1991.
112. Stinchcomb TG, Roeske JC. Values of "S," 〈z1〉, and 〈(z1)2〉 for dosimetry using alpha-particle emitters. Med Phys. 1999;26:1960-1971.
113. Fisher DR. Specific energy distributions for alpha emitters in the dog lung. Ann Occup Hyg. 1988;32(suppl 1):1095-1104.
114. Humm JL. A microdosimetric model of astatine-211 labeled antibodies for 0radioimmunotherapy. Int J Radiat Oncol Biol Phys. 1987;13:1767-1773.
115. Stinchcomb TG, Roeske JC. Survival of alpha particle irradiated cells as a function of the shape and size of the sensitive volume (nucleus). Radiat Prot Dosimetry. 1995;62:157-164.
116. Aubineau-Laniece I, Pihet P, Winkler R, Hofmann W, Charlton DE. Monte Carlo code for microdosimetry of inhaled alpha emitters. Radiat Prot Dosimetry. 2002;99:463-467.
117. Fakir H, Hofmann W, Aubineau-Laniece I. Modelling the effect of non-uniform radon progeny activities on transformation frequencies in human bronchial airways. Radiat Prot Dosimetry. 2006;121:221-235.
118. Fakir H, Hofmann W, Aubineau-Laniece I. Microdosimetry of radon progeny alpha particles in bronchial airway bifurcations. Radiat Prot Dosimetry. 2005;117:382-394.
119. Fakir H, Hofmann W, Caswell RS, Aubineau-Laniece I. Microdosimetry of inhomogeneous radon progeny distributions in bronchial airways. Radiat Prot Dosimetry. 2005;113:129-139.
120. Palm S, Humm JL, Rundqvist R, Jacobsson L. Microdosimetry of astatine-211 single-cell irradiation: role of daughter polonium-211 diffusion. Med Phys. 2004;31:218-225.
121. Iyer R, Lehnert BE. Alpha-particle-induced increases in the radioresistance of normal human bystander cells. Radiat Res. 2002;157:3-7.
122. Azzam EI, de Toledo SM, Gooding T, Little JB. Intercellular communication is involved in the bystander regulation of gene expression in human cells exposed to very low fluences of alpha particles. Radiat Res. 1998;150:497-504.
123. Utteridge TD, Charlton DE, Allen BJ. Monte Carlo modeling of the effects of injected short-, medium- and longer-range alpha-particle emitters on human marrow at various ages. Radiat Res. 2001;156:413-418.
124. Hamacher KA, Sgouros G. A schema for estimating absorbed dose to organs following the administration of radionuclides with multiple unstable daughters: a matrix approach. Med Phys. 1999;26:2526-2528.
125. Fisher DR, Sgouros G. Dosimetry of radium-223 and progeny. In: Stelson AT, Stabin MG, Sparks RB, eds. Proceedings of the Sixth International Radiopharmaceutical Dosimetry Symposium. Gatlinburg, TN: U.S. Department of Energy and Oak Ridge Associated Universities; 1999:375-391.
126. Sgouros G. Long-lived alpha emitters in radioimmunotherapy: the mischievous progeny. Cancer Biother Radiopharm. 2000;15:219-221.
127. 225Ac-HuM195, in nonhuman primates. J Nucl Med. 2004;45:129-137.
128. Hamacher KA, Den RB, Den EI, Sgouros G. Cellular dose conversion factors for alpha-particle-emitting radionuclides of interest in radionuclide therapy. J Nucl Med. 2001;42:1216-1221.
129. 227Th. Int J Radiat Biol Relat Stud Phys Chem Med. 1971;20:233-243.
130. 227Th-p-benzyl-DOTA-rituximab for low-dose rate alpha-particle radioimmunotherapy. Nucl Med Biol. 2006;33:271-279.
131. Dahle J, Borrebaek J, Jonasdottir TJ, et al. Targeted cancer therapy with a novel low dose rate alpha-emitting radioimmunoconjugate. Blood. 2007;110:2049-2056.
132. Siegel JA, Thomas SR, Stubbs JB, et al. MIRD pamphlet no. 16: techniques for quantitative radiopharmaceutical biodistribution data acquisition and analysis for use in human radiation dose estimates. J Nucl Med. 1999;40(suppl):37S-61S.
133. Sgouros G. Treatment planning for internal emitter therapy: methods, applications and clinical implications. In: Schafke-Stelson AT, Watson EE, eds. Proceedings of the 6th International Radiopharmaceutical Dosimetry Symposium, May 7-10, 1996, Gatlinburg, TN. Oak Ridge, TN: Oak Ridge Associated Universities; 1996:13-24.
134. Sgouros G. Radioimmunotherapy of micrometastases. In: Riva P, ed. Cancer Radioimmunotherapy: Present and Future. Newark, NJ: Harwood Academic Publishers; 1998:191-207.
135. 131I-19-iodocholesterol: the pitfalls of using tissue concentration data [reply]. J Nucl Med. 1975;16:248-249.
136. 213Bi-HuM195 (anti-CD33) in patients with leukemia. J Nucl Med. 1999;40:1935-1946.
137. Patton PW, Rajon DA, Shah AP, Jokisch DW, Inglis BA, Bolch WE. Site-specific variability in trabecular bone dosimetry: considerations of energy loss to cortical bone. Med Phys. 2002;29:6-14.
138. Bolch WE, Patton PW, Rajon DA, Shah AP, Jokisch DW, Inglis BA. Considerations of marrow cellularity in 3-dimensional dosimetric models of the trabecular skeleton. J Nucl Med. 2002;43:97-108.
139. Shah AP, Patton PW, Rajon DA, Bolch WE. Adipocyte spatial distributions in bone marrow: implications for skeletal dosimetry models. J Nucl Med. 2003;44:774-783.
140. Shah AP, Rajon DA, Patton PW, Jokisch DW, Bolch WE. Accounting for beta-particle energy loss to cortical bone via paired-image radiation transport (PIRT). Med Phys. 2005;32:1354-1366.
141. Watchman CJ, Jokisch DW, Patton PW, Rajon DA, Sgouros G, Bolch WE. Absorbed fractions for alpha-particles in tissues of trabecular bone: considerations of marrow cellularity within the ICRP reference male. J Nucl Med. 2005; 46:1171-1185.
142. Bolch WE, Eckerman KF, Sgouros G, Thomas SR. MIRD pamphlet no. 21: a generalized schema for radiopharmaceutical dosimetry - standardization of nomenclature. J Nucl Med. 2009;50:477-484.
143. Eckerman KF, Endo A. MIRD: Radionuclide Data and Decay Schemes. Reston, VA: Society of Nuclear Medicine; 2007.
144. Snyder WS, Fisher HL, Ford MR, Warner GG. Estimates of absorbed fractions for monoenergetic photon sources uniformly distributed in various organs of a heterogeneous phantom. J Nucl Med. 1969;10(suppl):7-52.
145. Bouchet LG, Jokisch DW, Bolch WE. A three-dimensional transport model for determining absorbed fractions of energy for electrons within trabecular bone. J Nucl Med. 1999;40:1947-1966.
146. Snyder WS, Ford MR, Warner GG. MIRD Pamphlet No. 5, Revised: Estimates of Specific Absorbed Fractions for Photon Sources Uniformly Distributed in Various Organs of a Heterogeneous Phantom. New York, NY: Society of Nuclear Medicine; 1978.
147. Sgouros G, Howell RW, Bolch WE, Fisher DR. MIRD commentary: proposed name for a dosimetry unit applicable to deterministic biological effects - the Barendsen (Bd). J Nucl Med. 2009;50:485-487.
148. Kneifel S, Cordier D, Good S, et al. Local targeting of malignant gliomas by the diffusible peptidic vector 1,4,7,10-tetraazacyclododecane-1-glutaric acid-4,7,10-triacetic acid-substance P. Clin Cancer Res. 2006;12:3843-3850.
149. 213Bi-labelled anti-CD19-and anti-CD20-CHX-A″-DTPA conjugates [abstract]. Abstracts of Papers of the American Chemical Society. 2003;225:U261.
150. Allen BJ, Raja C, Rizvi S, et al. Intralesional targeted alpha therapy for metastatic melanoma. Cancer Biol Ther. 2005;4:1318-1324.
151. Bruland OS, Nilsson S, Fisher DR, Larsen RH. High-linear energy transfer irradiation targeted to skeletal metastases by the alpha-emitter Ra-223: adjuvant or alternative to conventional modalities? Clin Cancer Res. 2006;12(suppl): 6250S-6257S.
152. Nilsson S, Franzen L, Parker C, et al. Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study. Lancet Oncol. 2007;8:587-594.
153. Goodhead DT. Talk 23, Alpha Emitters, from Session 6, Effects from Specific Sources of Internal Radiation. Presented at: CERRIE Workshop; July 21-23, 2003; Oxford, U.K.
154. Powsner RA, Powsner ER. Essentials of Nuclear Medicine Physics. Malden MA: Blackwell Science, Inc.; 1998.
155. Cole A, ed. Theoretical and Experimental Biophysics. New York, NY: Marcel Dekker, Inc.; 1967.